Axsome Therapeutics, Inc.
AXSM
$158.88
$1.010.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.22% | 26.19% | 19.98% | 6.11% | -20.05% |
| Total Depreciation and Amortization | 13.90% | 16.24% | 16.50% | 17.95% | 16.45% |
| Total Amortization of Deferred Charges | -50.64% | -22.46% | 0.98% | 3.03% | 2.56% |
| Total Other Non-Cash Items | -10.69% | -15.76% | 1.31% | -0.62% | 1.40% |
| Change in Net Operating Assets | -168.88% | -113.54% | -167.15% | 217.85% | 217.91% |
| Cash from Operations | 27.26% | 23.85% | 27.98% | 38.61% | 11.49% |
| Capital Expenditure | -77.78% | -77.73% | 10.80% | 16.26% | 53.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -77.78% | -77.73% | 10.80% | 16.26% | 53.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -33,648.69% | -39,885.00% | -55,357.88% | -653.37% | -- |
| Issuance of Common Stock | 78.36% | 125.31% | 120.93% | -61.34% | -73.65% |
| Repurchase of Common Stock | -79.91% | -78.40% | -73.97% | -157.93% | -115.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -70.18% | -100.20% | -48.42% | 57.56% | 62.77% |
| Cash from Financing | 75.42% | 127.84% | 132.95% | -68.27% | -82.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 110.70% | 97.68% | 89.59% | -135.95% | -138.22% |